Nanotechnology is producing revolutionary materials for industry, consumers, and medicine, yet repeated concerns have been voiced about the potential effects of nanomaterials on human health and the environment. These concerns require careful evaluation, using the best science available and the insights and expertise of an organization with a strong foundation in traditional toxicology, as well as complementary skills in the medical and physical sciences, experimental design, regulatory policy, and risk communication.Experts in the Field
Intertox, Inc. is currently supporting effective actions to reduce possible Environmental Health and Safety (EHS) risks from nanomaterials through a variety of efforts, most recently assisting with the development of science-based guidelines and standards through the American National Standards Institute (ANSI) Technical Advisory Group (TAG) 229, the sponsor of the United States delegation to the International Organization for Standardization (ISO). Along with a position in Working Group 3, which focuses on environment, safety and health issues, Intertox is involved with other EHS movements, including contributing to panels and committees organized by the US EPA, US Army Corps of Engineers, and Health Canada. Intertox has also provided comments to the National Nanotechnology Coordinating Office, FDA, and the European Commission.
Clients and Partnerships
Intertox’s involvement in EHS also extends to a number of projects and partnerships with first tier laboratories focused on the testing of nanomaterials, both small and large industries, and the US government. By assessing occupational and consumer products, conducting ‘cradle to grave’ assessments, evaluating occupational exposures, and developing experimental designs for animal studies, we’ve informed and assisted our clients and partners in making important decisions regarding their products as they relate to nanotechnology, human health, and safety.
Experience
Intertox’s experience stretches beyond the evaluation of nanomaterials and consumer products, and into the realm of research and development. We’ve assisted in developing sampling programs to monitor occupational exposures and minimize risk associated with nanoparticles and nano-silver, and are currently in the development stage of a decision risk support system that quantifies nanomaterial risks through the product life cycle. Intertox has also developed a decision analysis approach based on nanomaterial management, and a “periodic table” for nanomaterial classification. This development, and other ongoing research, is viable to understanding nanomaterials and how they affect our everyday lives.
Mission
We have developed sound science strategies to protect human and environmental health, and have experience in situations where scientific data is limited, data gaps are present, and regulatory policies are developing. Our knowledge, training, and experience in EHS nanotechnology, combined with our history and reputation as an independent research organization, allows Intertox the ability to guide stakeholders through this rapidly changing landscape.